Exportación Completada — 

Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial

BACKGROUND: Regorafenib is an oral multikinase inhibitor for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, irinotecan, oxaliplatin, monoclonal antibodies targeting vascular endothelial growth factor, and monoclonal antibodies targeting epidermal growth factor recepto...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Trials
Asıl Yazarlar: Ma, Cheng-Jen, Chang, Tsung-Kun, Tsai, Hsiang-Lin, Su, Wei-Chih, Huang, Ching-Wen, Yeh, Yung-Sung, Chang, Yu-Tang, Wang, Jaw-Yuan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2019
Konular:
Study Protocol
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6923824/
https://ncbi.nlm.nih.gov/pubmed/31856912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-019-3917-z
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller